Nanomedicine(s) under the Microscope

被引:701
作者
Duncan, Ruth [1 ]
Gaspar, Rogerio [2 ]
机构
[1] Ctr Invest Principe Felipe, Polymer Therapeut Lab, E-46012 Valencia, Spain
[2] Univ Lisbon, Nanomed & Drug Delivery Syst Grp, Fac Pharm, P-1649003 Lisbon, Portugal
关键词
nanomedicine; nanopharmaceutical; nanoimaging agent; theranostic; regulation; cancer; N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER-DOXORUBICIN; PEGYLATED LIPOSOMAL DOXORUBICIN; SOLUBLE SYNTHETIC-POLYMERS; OXIDE NANOPARTICLES SPIONS; IN-VIVO BIODISTRIBUTION; CARBON NANOTUBES; DRUG-DELIVERY; QUANTUM DOTS; PHASE-I; COMPLEMENT ACTIVATION;
D O I
10.1021/mp200394t
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable of delivering new diagnostics, treatments for unmanageable diseases, and opportunities for tissue repair or highly dangerous nanoparticles, nanorobots, or nanoelectronic devices that will wreak havoc in the body. The truth lies firmly between these two extremes. Rational design of "nanomedicines" began almost half a century ago, and >40 products have completed the complex journey from lab to routine clinical use. Here we critically review both nanomedicines in clinical use and emerging nanosized drugs, drug delivery systems, imaging agents, and theranostics with unique properties that promise much for the future. Key factors relevant to the design of practical nanomedicines and the regulatory mechanisms designed to ensure safe and timely realization of healthcare benefits are discussed.
引用
收藏
页码:2101 / 2141
页数:41
相关论文
共 504 条
[1]   Nanomaterial standards for efficacy and toxicity assessment [J].
Adiseshaiah, Pavan P. ;
Hall, Jennifer B. ;
McNeil, Scott E. .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2010, 2 (01) :99-112
[2]   Targeted cancer therapies [J].
Aggarwal, Saurabh .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (06) :427-428
[3]   Functional Delivery of siRNA in Mice Using Dendriworms [J].
Agrawal, Amit ;
Min, Dal-Hee ;
Singh, Neetu ;
Zhu, Haihao ;
Birjiniuk, Alona ;
von Maltzahn, Geoffrey ;
Harris, Todd J. ;
Xing, Deyin ;
Woolfenden, Stephen D. ;
Sharp, Phillip A. ;
Charest, Alain ;
Bhatia, Sangeeta .
ACS NANO, 2009, 3 (09) :2495-2504
[4]  
Akinc A, 2002, BIOTECHNOL BIOENG, V78, P503, DOI 10.1002/bit.20215
[5]   Safety aspects of pegylated liposomal doxorubicin in patients with cancer [J].
Alberts, DS ;
Garcia, DJ .
DRUGS, 1997, 54 (Suppl 4) :30-35
[6]  
Alexiou C, 2000, CANCER RES, V60, P6641
[7]   Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[8]   Quantum dots as cellular probes [J].
Alivisatos, AP ;
Gu, WW ;
Larabell, C .
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, 2005, 7 :55-76
[9]  
Allemann E, 1997, J BIOMED MATER RES, V37, P229, DOI 10.1002/(SICI)1097-4636(199711)37:2<229::AID-JBM12>3.0.CO
[10]  
2-9